Physician profile
Christopher Emerson
NPI 1689650392
$2,812.35
in general payments reported to CMS, 2019-2025
28 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $117 · 2023: $729 · 2024: $1,375 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $449.99 | 2021-2024 | |
| Procept Biorobotics Corporation | $329.68 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Axsome Therapeutics, INC. | $312.84 | 2024-2025 | Auvelity |
| Myriad Genetic Laboratories, INC. | $294.09 | 2022-2024 | Myrisk, Prolaris |
| Otsuka America Pharmaceutical, INC. | $217.09 | 2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $192.53 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $136.77 | 2023-2024 | Xtandi |
| Sumitomo Pharma America, INC. | $116.93 | 2023-2025 | Orgovyx |
| Blue Earth Diagnostics | $88.20 | 2024-2025 | Posluma |
| Endo Pharmaceuticals INC. | $80.14 | 2022-2023 | Xiaflex |
| Tolmar, INC. | $78.89 | 2024-2025 | Eligard, Jatenzo |
| Janssen Biotech, INC. | $77.09 | 2022-2025 | Erleada |
| Boston Scientific Corporation | $75.13 | 2023 | Lithovue |
| Olympus America INC. | $40.67 | 2023-2024 | Itind System |
| Urogen Pharma, INC. | $37.12 | 2023-2024 | Jelmyto |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.70 | 2025 | |
| Coloplast Corp | $32.25 | 2023-2024 | Speedicath |
| Dentsply Ih INC. | $27.08 | 2024 | Lofric |
| 180 Medical, INC. | $25.88 | 2024 | |
| Merck Sharp & Dohme LLC | $21.55 | 2024 | Keytruda |
| Laborie Medical Technologies Corp. | $20.65 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Immunitybio, INC. | $19.61 | 2024 | |
| Dendreon Pharmaceuticals LLC | $19.21 | 2022 | |
| Progenics Pharmaceuticals, INC. | $18.54 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.59 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.58 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.80 | 2025 | Adstiladrin |
| Axonics, INC. | $13.75 | 2024 | Axonics, Bulkamid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Emerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.